Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SiBone SIBN

Healthcare  —  Medical Devices
18.59 0.07 0.38% as of 25 Sep
Market cap
$830.0M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

SiBone (SIBN) Business Profile

Updated before January 2025

Company Overview

SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company that specializes in the development and commercialization of innovative solutions for the treatment of musculoskeletal disorders. Founded in 2008 and headquartered in Santa Clara, California, SI-BONE has established itself as a leader in the field of sacroiliac (SI) joint dysfunction treatment. The company was co-founded by Dr. Mark Reiley, a renowned orthopedic surgeon, who identified the need for minimally invasive solutions to address SI joint pain. SI-BONE’s leadership team includes experienced professionals from the medical device and healthcare industries, with Laura Francis serving as the Chief Executive Officer (CEO) and Jeffrey Dunn as the Executive Chairman of the Board.

Core Business Segments

SI-BONE focuses on providing innovative medical devices and solutions for the treatment of SI joint dysfunction and related musculoskeletal disorders. The company’s core business segments include:

iFuse Implant System

The iFuse Implant System is SI-BONE’s flagship product and a minimally invasive surgical solution for SI joint fusion. The system is designed to stabilize and fuse the SI joint, providing long-term relief for patients suffering from chronic SI joint pain. Key features of the iFuse Implant System include:

  • Triangular Titanium Implants: These implants are designed to provide superior stability and minimize micromotion.
  • Minimally Invasive Procedure: The system allows for a less invasive surgical approach, reducing recovery time and improving patient outcomes.
  • Proven Clinical Efficacy: The iFuse Implant System has been supported by numerous clinical studies demonstrating its safety and effectiveness.

iFuse-3D Implant

The iFuse-3D Implant is an advanced version of the iFuse Implant System, featuring a 3D-printed design that enhances bone integration and stability. This product represents SI-BONE’s commitment to leveraging cutting-edge technology to improve patient outcomes.

Ancillary Products and Services

In addition to its implant systems, SI-BONE offers a range of ancillary products and services to support surgeons and healthcare providers. These include surgical instruments, training programs, and educational resources to ensure the successful adoption and utilization of SI-BONE’s solutions.

Business Model

SI-BONE operates on a business model that integrates innovative medical devices with comprehensive support services. The company generates revenue primarily through the sale of its implant systems and related surgical instruments. Key aspects of SI-BONE’s business model include:

  • Direct Sales Force: SI-BONE employs a dedicated sales team to promote its products and provide support to healthcare providers.
  • Clinical Education and Training: The company invests in training programs and educational initiatives to ensure that surgeons are well-equipped to perform SI joint fusion procedures using SI-BONE’s products.
  • Research and Development: SI-BONE allocates significant resources to R&D to drive innovation and expand its product portfolio.

Strategic Direction

SI-BONE is focused on achieving sustainable growth and expanding its market presence. Key elements of the company’s strategic direction include:

  • Market Expansion: SI-BONE aims to increase adoption of its products by expanding into new geographic markets and targeting underserved patient populations.
  • Product Innovation: The company is committed to developing new products and enhancing existing solutions to address a broader range of musculoskeletal disorders.
  • Sustainability Goals: SI-BONE is dedicated to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.
  • Partnerships and Collaborations: The company seeks to establish strategic partnerships with healthcare providers and industry stakeholders to drive growth and innovation.

Competitive Landscape

SI-BONE operates in a competitive market that includes both established medical device companies and emerging players. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of products for spinal and musculoskeletal disorders.
  • Globus Medical: A company specializing in innovative solutions for musculoskeletal conditions, including spinal implants and surgical instruments.
  • Zimmer Biomet: A leading provider of orthopedic and musculoskeletal healthcare solutions.

Despite the competition, SI-BONE differentiates itself through its focus on the SI joint and its commitment to clinical excellence and innovation.

Risk Factors

SI-BONE faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily reliant on the success of its iFuse Implant System, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: SI-BONE operates in a highly regulated industry, and changes in regulatory requirements could affect its ability to market and sell its products.
  • Supply Chain Disruptions: The company is exposed to risks related to supply chain disruptions, which could impact product availability and delivery timelines.
  • Economic Conditions: Macroeconomic factors, such as healthcare spending and reimbursement policies, could influence demand for SI-BONE’s products.

Recent Developments

SI-BONE has made significant strides in advancing its product portfolio and corporate strategy. Recent developments include:

  • Launch of New Products: The company has introduced new versions of its iFuse Implant System, incorporating advanced materials and designs to improve patient outcomes.
  • Clinical Research: SI-BONE continues to invest in clinical studies to validate the safety and efficacy of its products, further strengthening its position in the market.
  • Global Expansion: The company has expanded its presence in international markets, including Europe and Asia, to drive growth and reach more patients.

Investment Considerations

Investors considering SI-BONE as a potential investment should weigh the following strengths and risks:

Strengths

  • Market Leadership: SI-BONE is a pioneer in the SI joint treatment space, with a strong track record of innovation and clinical success.
  • Growing Market Opportunity: The global market for SI joint fusion is expected to grow, driven by increasing awareness and demand for minimally invasive solutions.
  • Robust Product Portfolio: The company’s iFuse Implant System and related products are well-regarded for their safety and efficacy.

Risks

  • Market Concentration: SI-BONE’s reliance on a single product category could expose it to market risks.
  • Regulatory and Competitive Pressures: The company operates in a challenging regulatory environment and faces competition from larger players.
  • Economic Uncertainty: Changes in healthcare policies and economic conditions could impact demand for SI-BONE’s products.

Conclusion

SI-BONE is a leading medical device company with a strong focus on innovation and clinical excellence. The company’s iFuse Implant System has revolutionized the treatment of SI joint dysfunction, providing significant benefits to patients and healthcare providers. With a robust product portfolio, a commitment to R&D, and a strategic focus on market expansion, SI-BONE is well-positioned for future growth. However, investors should carefully consider the risks associated with the company’s market concentration and regulatory environment. Overall, SI-BONE’s strong market position and growth potential make it a compelling player in the medical device industry.